Linden Thomas Advisory Services’s Halozyme HALO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$2.15M Sell
27,478
-163
-0.6% -$11.1K 0.17% 194
2026
Q1
$1.79M Sell
27,641
-7,162
-21% -$505K 0.17% 213
2025
Q4
$2.34M Sell
34,803
-441
-1% -$29.7K 0.24% 122
2025
Q3
$2.58M Buy
35,244
+9
+0% +$598 0.26% 111
2025
Q2
$1.83M Sell
35,235
-646
-2% -$36.8K 0.2% 161
2025
Q1
$2.29M Buy
35,881
+890
+3% +$51.7K 0.3% 102
2024
Q4
$1.67M Sell
34,991
-349
-1% -$17.9K 0.21% 171
2024
Q3
$2.02M Buy
35,340
+12
+0% +$688 0.28% 119
2024
Q2
$1.85M Sell
35,328
-7,169
-17% -$314K 0.29% 108
2024
Q1
$1.73M Buy
42,497
+40
+0.1% +$1.5K 0.28% 124
2023
Q4
$1.57M Buy
42,457
+7
+0% +$264 0.29% 127
2023
Q3
$1.62M Buy
42,450
+5,126
+14% +$210K 0.36% 79
2023
Q2
$1.35M Buy
37,324
+181
+0.5% +$6.18K 0.3% 129
2023
Q1
$1.42M Buy
37,143
+894
+2% +$41.9K 0.35% 108
2022
Q4
$2.06M Buy
+36,249
New +$1.86M 0.58% 29

Other funds holding HALO

Linden Thomas Advisory Services's HALO Position: Q2 2026 in Review

Linden Thomas Advisory Services reduced its Halozyme (HALO) stake by 0.59% in Q2 2026, selling an estimated $11.1K and leaving 27,478 shares worth $2.15M. The position accounts for 0.17% of the portfolio, ranked #194.

Linden Thomas Advisory Services first reported a position in HALO in Q4 2022 and has held it in 15 quarters since. The position peaked at $2.58M in Q3 2025. 671 funds tracked by Wall St. Rank hold HALO as of Q2 2026.

  • Linden Thomas Advisory Services held 27,478 shares of Halozyme worth $2.15M as of Q2 2026.
  • Linden Thomas Advisory Services sold 163 Halozyme shares in Q2 2026, an estimated $11.1K.
  • Halozyme made up 0.17% of Linden Thomas Advisory Services's portfolio in Q2 2026, its #194 holding.
  • Linden Thomas Advisory Services first reported a position in Halozyme in Q4 2022 and has held it in 15 quarters since.
  • Linden Thomas Advisory Services's Halozyme position peaked at $2.58M in Q3 2025.
  • 671 funds tracked by Wall St. Rank held Halozyme as of Q2 2026.

Based on Linden Thomas Advisory Services's 13F filing for Q2 2026, filed 16 Jul 2026.